0H8T.L

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$6M	-32.2%	$-0.66	$-0.87–$-0.29	—	1
2027	$6M	-2.9%	$-0.75	$-0.98–$-0.33	—	1
2028	$7M	+13.7%	$-0.78	$-1.02–$-0.34	—	1
2029	$25M	+287.1%	$-0.85	$-1.12–$-0.37	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 5 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-06	$-0.16	$-0.15	+6.3%
2026-05-07	$-0.16	$-0.15	+4.9%
2026-02-26	$-0.14	$-0.16	-10.6%
2025-11-06	$-0.14	$-0.12	+11.9%
2025-08-07	$-0.13	$-0.13	+2.2%
2025-05-08	$-0.15	$-0.12	+21.2%
2025-02-27	$-0.29	$-1.01	-252.3%
2024-11-06	$-0.01

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
0H8T.LAclaris Therapeutics, Inc.	$5.51	+8.79%	$688M	—
0H7R.LAbeona Therapeutics Inc.	$5.47	+2.24%	$262M	—
0H8I.LAccuray Incorporated	$0.24	+1.71%	$28M	—
0HIY.LAtara Biotherapeutics Inc	$10.33	+2.89%	$93M	—
0HX7.LAdicet Bio, Inc.	$9.16

Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in the United States, dedicated to discovering and advancing novel therapeutic agents for immune-inflammatory diseases. The company operates through two distinct divisions: Therapeutics and Contract Research. The Therapeutics segment focuses on identifying and developing cutting-edge treatments to address significant unmet medical needs within the realm of immunological and inflammatory conditions. Complementing this, the Contract Research segment offers specialized laboratory services. Aclaris boasts a robust development pipeline, featuring several key drug candidates. These include Zunsemetinib, an MK2 inhibitor, currently being developed to treat moderate to severe rheumatoid and psoriatic arthritis, as well as hidradenitis suppurativa. Another significant asset is ATI-1777, a soft JAK 1/3 inhibitor, targeting moderate to severe atopic dermatitis. Furthermore, the company is progressing with ATI-2138, an ITK/TXK/JAK3 inhibitor for T cell-mediated autoimmune diseases; a Gut-Biased Program aimed at inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, intended for pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics maintains its principal office in Wayne, Pennsylvania.

www.aclaristx.com

Employees: 73
IPO / List date: Jan 29, 2018
HQ: US

Held by traders on TradeandTell

No one on the platform currently holds 0H8T.L.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in 0H8T.L as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded 0H8T.L yet.